FASTOMEGA™

What is FASTOMEGA™?

■FASTOMEGA™ is a Medical Food intended for reducing inflammatory response caused by trauma through dietary management. It has been determined to be Generally Recognized as Safe (GRAS) and has acquired its Certificate of Free Sale from the US Food and Drug Administration (FDA). FASTOMEGA™ is a Medical Food product specifically formulated for improving the systemic inflammatory reaction and sequelae associated with some acute conditions (e.g., after ischemic accidents or after surgical or other traumatic injuries).

■FASTOMEGA™ is a novel Omega-3 PUFA containing emulsion preparation. The main feature lies in its ability to be rapidly absorbed. Omega-3 can be enriched to cell membrane within one day of consumption and such enrichment reaches an optimum level in as few as five days. The product is especially suitable for Omega-3 deficient population who are in urgent need of raising Omega-3 polyunsaturated fatty acid levels in a short period of time (e.g. patients pending for elective surgery, patients with sudden or acute injury etc.)

■FASTOMEGA™ provides 1 gram of Docosahexaenoic acid (DHA), 1 gram of Eicosapentaenoic acid (EPA) and 1 gram of Medium-chain triglycerides (MCT), with a greater than 90% purity of Omega-3 polyunsaturated fatty acid, sugar-free and preservative-free formulation.

■FASTOMEGA™ is intended for dietary use as an enteral nutritional support. As an effective anti-inflammatory agent for excessive inflammation, its innovative formulation helps DHA and EPA to be rapidly absorbed onto cell membrane with a safe profile. Cellular concentration of DHA and EPA reach to an optimum level after 5 days of continuous intake, and the concentration level continues to increase in the following three weeks through daily supplementation.

■FASTOMEGA™ finished product is produced by an SQF Level 3 Quality Certified USA manufacturer which represents the highest standard in terms of food quality and safety. Raw material of FASTOMEGA™ undergoes a purification process in an FDA approved cGMP facility which utilizes supercritical carbon dioxide fluid extraction (SFE) and supercritical fluid chromatography (SFC) to ensure that purification of Omega-3 fatty acids is carried out without exposure to any oxygen and organic solvents under non-high temperature conditions. This protects Omega-3 polyunsaturated fatty acids from oxidation, microbial contamination as well as ensures that there is no heavy metal residue.

Highlights of FASTOMEGA™

More Enrichment, Faster Absorption, Better Effectiveness, Higher Value

■More Enrichment: more DHA and EPA is enriched onto human cell membrane, 1.2 to 2 times more than conventional fish oil capsules.

FASTOMEGA™ provides 1 gram of DHA (Docosahexaenoic acid) and 1 gram EPA (Eicosapentaenoic acid) and 1 gram of MCT (Medium-chain triglycerides). MCT facilitates rapid enrichment of DHA and EPA to cell membrane. A randomized controlled trial of 48 subjects showed an 8-fold increase of EPA from baseline for the group taking FASTOMEGA™, which is 200% more than control group taking ordinary Omega-3 polyunsaturated fatty acid soft capsules. Similarly, DHA content is 2 times higher than baseline in the group taking FASTOMEGA™, which is 120% more than that of the control group.

Faster Absorption: FASTOMEGA™ more rapidly enriches DHA and EPA onto cell membrane compared with conventional fish oil capsules.

FASTOMEGA™ is an emulsion product with small particle size. It could be rapidly absorbed by the small intestine bypassing the emulsification process that involves bile. Cellular concentration of Omega-3 fatty acids reaches to a substantially higher concentration in as few as five days. In an open-label, self-controlled clinical study with 40 subjects, intracellular concentration of EPA has been shown to double within 7 days of intake of FASTOMEGA™, which is an outcome never shown by consumption of fish oil capsules.

Better Effectiveness: FASTOMEGA™ is able to attenuate proinflammatory cytokines and reduce a series of surgical complications.

Patients who take high-purity Omega-3 polyunsaturated fatty acids at a dose equivalent to FASTOMEGA™ (4 g) for consecutive 4 weeks or more prior to and post surgery, EPA and DHA levels on the cell membrane of organ tissues were shown to increase by 300% and 56.5%, respectively. In addition, tissues showed greater expression and activity of key antioxidant/anti-inflammatory enzymes. Omega-6 polyunsaturated fatty acid/Omega-3 polyunsaturated fatty acid ratio drops from close to 10/1 to about 4/1 in platelet after 28 days of use. Surgical patients showed shorter ICU stay, and reduced complications.

Higher Value: higher safety and cost-effectiveness, and effectively reduces overall cost of treatment.

FASTOMEGA™ is a cost-effective and safe Omega-3 emulsion product. The safety of FASTOMEGA™ was demonstrated in an open label clinical study with 40 subjects in a period of 4 weeks. Except transient belching, satiety and mild diarrhea, it exhibits a safety profile with no other side effects. Furthermore, it has been shown that enteral nutritional support prior to surgery could reduce risks. For patients with known malnutrition, administering enteral nutrition before surgery could reduce the risk of postoperative complications by 20%. Preoperative administration of Omega-3 fatty acids in high risk surgical patient help reduce postoperative infection, as well as shorten the period of hospital stay, which are shown in a recent meta-analysis research article [1].

 

What are the advantages of FASTOMEGA™

■MCT possesses the ability to rapidly enter cell membrane. MCT in FASTOMEGA™ is able to facilitate omega-3 fatty acids’ rapid enrichment to cell membrane, which is thousand times faster what otherwise would be for conventional Omega-3 fatty acids. This is one of the reasons that FASTOMEGA™ is able to facilitate rapid enrichment of Omega-3 fatty acid to cell membranes.

■FASTOMEGA™ is an emulsion with small particle size, which bears resemblance to the size of the triglyceride fatty acid remnants. It bypasses the metabolic process by lipoprotein lipase (LPL), nor be converted into fatty acids which are transported into extrahepatic tissue and used as energy source. Instead, it directly enters the liver and engages in metabolization, exerting effects on numerous biologically important pathways. This is another important reason that FASTOMEGA™ can be absorbed faster and act faster.

References